Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Ad26.Filo and MVA-BN-Filo Prime-Boost Regimens in Healthy Adults
NCT02860650Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- May 2017
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad26.Filo and Mvabea in Ebola virus disease (EVD) and Marburg virus disease (MVD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse events, Number of Participants With Reactogenicity (Solicited Local and Systemic Adverse Events) and 1 more. Started Aug 2016; status: completed.
02
Drugs
Ad26.FiloMvabea
03
Conditions
Ebola virus disease (EVD)Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT02860650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860650.